Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
5,167
archived clinical trials in
Liver Cancer

Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery
Randomized Phase II Trial of Single Agent MEK Inhibitor Trametinib (GSK1120212) Vs 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer
Status: Enrolling
Updated:  1/5/2017
Mount Carmel Health Center West
mi
from
Columbus, OH
Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery
Randomized Phase II Trial of Single Agent MEK Inhibitor Trametinib (GSK1120212) Vs 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer
Status: Enrolling
Updated: 1/5/2017
Mount Carmel Health Center West
mi
from
Columbus, OH
Click here to add this to my saved trials
Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery
Randomized Phase II Trial of Single Agent MEK Inhibitor Trametinib (GSK1120212) Vs 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer
Status: Enrolling
Updated:  1/5/2017
Dayton NCI Community Oncology Research Program
mi
from
Dayton, OH
Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery
Randomized Phase II Trial of Single Agent MEK Inhibitor Trametinib (GSK1120212) Vs 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer
Status: Enrolling
Updated: 1/5/2017
Dayton NCI Community Oncology Research Program
mi
from
Dayton, OH
Click here to add this to my saved trials
Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery
Randomized Phase II Trial of Single Agent MEK Inhibitor Trametinib (GSK1120212) Vs 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer
Status: Enrolling
Updated:  1/5/2017
Genesis Healthcare System Cancer Care Center
mi
from
Zanesville, OH
Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery
Randomized Phase II Trial of Single Agent MEK Inhibitor Trametinib (GSK1120212) Vs 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer
Status: Enrolling
Updated: 1/5/2017
Genesis Healthcare System Cancer Care Center
mi
from
Zanesville, OH
Click here to add this to my saved trials
Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery
Randomized Phase II Trial of Single Agent MEK Inhibitor Trametinib (GSK1120212) Vs 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer
Status: Enrolling
Updated:  1/5/2017
Providence Saint Vincent Medical Center
mi
from
Portland, OR
Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery
Randomized Phase II Trial of Single Agent MEK Inhibitor Trametinib (GSK1120212) Vs 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer
Status: Enrolling
Updated: 1/5/2017
Providence Saint Vincent Medical Center
mi
from
Portland, OR
Click here to add this to my saved trials
Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery
Randomized Phase II Trial of Single Agent MEK Inhibitor Trametinib (GSK1120212) Vs 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer
Status: Enrolling
Updated:  1/5/2017
Lowcountry Hematology Oncology PA-North Charleston
mi
from
Charleston, SC
Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery
Randomized Phase II Trial of Single Agent MEK Inhibitor Trametinib (GSK1120212) Vs 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer
Status: Enrolling
Updated: 1/5/2017
Lowcountry Hematology Oncology PA-North Charleston
mi
from
Charleston, SC
Click here to add this to my saved trials
Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery
Randomized Phase II Trial of Single Agent MEK Inhibitor Trametinib (GSK1120212) Vs 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer
Status: Enrolling
Updated:  1/5/2017
Spartanburg Medical Center
mi
from
Spartanburg, SC
Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery
Randomized Phase II Trial of Single Agent MEK Inhibitor Trametinib (GSK1120212) Vs 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer
Status: Enrolling
Updated: 1/5/2017
Spartanburg Medical Center
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery
Randomized Phase II Trial of Single Agent MEK Inhibitor Trametinib (GSK1120212) Vs 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer
Status: Enrolling
Updated:  1/5/2017
Methodist Hospital System
mi
from
Houston, TX
Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery
Randomized Phase II Trial of Single Agent MEK Inhibitor Trametinib (GSK1120212) Vs 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer
Status: Enrolling
Updated: 1/5/2017
Methodist Hospital System
mi
from
Houston, TX
Click here to add this to my saved trials
Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery
Randomized Phase II Trial of Single Agent MEK Inhibitor Trametinib (GSK1120212) Vs 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer
Status: Enrolling
Updated:  1/5/2017
University of Kansas Cancer Center - Lee's Summit
mi
from
Lee's Summit, MO
Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery
Randomized Phase II Trial of Single Agent MEK Inhibitor Trametinib (GSK1120212) Vs 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer
Status: Enrolling
Updated: 1/5/2017
University of Kansas Cancer Center - Lee's Summit
mi
from
Lee's Summit, MO
Click here to add this to my saved trials
Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery
Randomized Phase II Trial of Single Agent MEK Inhibitor Trametinib (GSK1120212) Vs 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer
Status: Enrolling
Updated:  1/5/2017
Michigan Cancer Research Consortium NCORP
mi
from
Ann Arbor, MI
Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery
Randomized Phase II Trial of Single Agent MEK Inhibitor Trametinib (GSK1120212) Vs 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer
Status: Enrolling
Updated: 1/5/2017
Michigan Cancer Research Consortium NCORP
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery
Randomized Phase II Trial of Single Agent MEK Inhibitor Trametinib (GSK1120212) Vs 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer
Status: Enrolling
Updated:  1/5/2017
Beaumont Hospital-Dearborn
mi
from
Dearborn, MI
Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery
Randomized Phase II Trial of Single Agent MEK Inhibitor Trametinib (GSK1120212) Vs 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer
Status: Enrolling
Updated: 1/5/2017
Beaumont Hospital-Dearborn
mi
from
Dearborn, MI
Click here to add this to my saved trials
Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery
Randomized Phase II Trial of Single Agent MEK Inhibitor Trametinib (GSK1120212) Vs 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer
Status: Enrolling
Updated:  1/5/2017
PeaceHealth Saint John Medical Center
mi
from
Longview, WA
Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery
Randomized Phase II Trial of Single Agent MEK Inhibitor Trametinib (GSK1120212) Vs 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer
Status: Enrolling
Updated: 1/5/2017
PeaceHealth Saint John Medical Center
mi
from
Longview, WA
Click here to add this to my saved trials
Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery
Randomized Phase II Trial of Single Agent MEK Inhibitor Trametinib (GSK1120212) Vs 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer
Status: Enrolling
Updated:  1/5/2017
Kootenai Cancer Clinic
mi
from
Sandpoint, ID
Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery
Randomized Phase II Trial of Single Agent MEK Inhibitor Trametinib (GSK1120212) Vs 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer
Status: Enrolling
Updated: 1/5/2017
Kootenai Cancer Clinic
mi
from
Sandpoint, ID
Click here to add this to my saved trials
Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery
Randomized Phase II Trial of Single Agent MEK Inhibitor Trametinib (GSK1120212) Vs 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer
Status: Enrolling
Updated:  1/5/2017
Reid Health
mi
from
Richmond, IN
Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery
Randomized Phase II Trial of Single Agent MEK Inhibitor Trametinib (GSK1120212) Vs 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer
Status: Enrolling
Updated: 1/5/2017
Reid Health
mi
from
Richmond, IN
Click here to add this to my saved trials
Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery
Randomized Phase II Trial of Single Agent MEK Inhibitor Trametinib (GSK1120212) Vs 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer
Status: Enrolling
Updated:  1/5/2017
Cancer Center of Kansas, PA - Wichita
mi
from
Wichita, KA
Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery
Randomized Phase II Trial of Single Agent MEK Inhibitor Trametinib (GSK1120212) Vs 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer
Status: Enrolling
Updated: 1/5/2017
Cancer Center of Kansas, PA - Wichita
mi
from
Wichita, KA
Click here to add this to my saved trials
Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery
Randomized Phase II Trial of Single Agent MEK Inhibitor Trametinib (GSK1120212) Vs 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer
Status: Enrolling
Updated:  1/5/2017
Lake Huron Medical Center
mi
from
Port Huron, MI
Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery
Randomized Phase II Trial of Single Agent MEK Inhibitor Trametinib (GSK1120212) Vs 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer
Status: Enrolling
Updated: 1/5/2017
Lake Huron Medical Center
mi
from
Port Huron, MI
Click here to add this to my saved trials
Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery
Randomized Phase II Trial of Single Agent MEK Inhibitor Trametinib (GSK1120212) Vs 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer
Status: Enrolling
Updated:  1/5/2017
Lakeland Hospital
mi
from
Saint Joseph, MI
Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery
Randomized Phase II Trial of Single Agent MEK Inhibitor Trametinib (GSK1120212) Vs 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer
Status: Enrolling
Updated: 1/5/2017
Lakeland Hospital
mi
from
Saint Joseph, MI
Click here to add this to my saved trials
Everolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable Solid Tumors Refractory to Standard Therapy
Phase I Trial of Everolimus, Gemcitabine, and Cisplatin for Patients With Solid Tumors Refractory to Standard Therapy
Status: Enrolling
Updated:  1/11/2017
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Everolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable Solid Tumors Refractory to Standard Therapy
Phase I Trial of Everolimus, Gemcitabine, and Cisplatin for Patients With Solid Tumors Refractory to Standard Therapy
Status: Enrolling
Updated: 1/11/2017
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Everolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable Solid Tumors Refractory to Standard Therapy
Phase I Trial of Everolimus, Gemcitabine, and Cisplatin for Patients With Solid Tumors Refractory to Standard Therapy
Status: Enrolling
Updated:  1/11/2017
Mayo Clinic Florida
mi
from
Jacksonville, FL
Everolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable Solid Tumors Refractory to Standard Therapy
Phase I Trial of Everolimus, Gemcitabine, and Cisplatin for Patients With Solid Tumors Refractory to Standard Therapy
Status: Enrolling
Updated: 1/11/2017
Mayo Clinic Florida
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Everolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable Solid Tumors Refractory to Standard Therapy
Phase I Trial of Everolimus, Gemcitabine, and Cisplatin for Patients With Solid Tumors Refractory to Standard Therapy
Status: Enrolling
Updated:  1/11/2017
The Mayo Clinic
mi
from
Rochester, MN
Everolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable Solid Tumors Refractory to Standard Therapy
Phase I Trial of Everolimus, Gemcitabine, and Cisplatin for Patients With Solid Tumors Refractory to Standard Therapy
Status: Enrolling
Updated: 1/11/2017
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Physiologic Assessment Following Gadoxetic Acid and Gadobenate Dimeglumine Administration
Physiologic Assessment Following Gadoxetic Acid and Gadobenate Dimeglumine Administration
Status: Enrolling
Updated:  1/12/2017
University of Michigan Hospital
mi
from
Ann Arbor, MI
Physiologic Assessment Following Gadoxetic Acid and Gadobenate Dimeglumine Administration
Physiologic Assessment Following Gadoxetic Acid and Gadobenate Dimeglumine Administration
Status: Enrolling
Updated: 1/12/2017
University of Michigan Hospital
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Zinc Supplements in Lowering Cadmium Levels in Smokers
Do Dietary Supplements of Zinc Reduce Serum Cadmium Levels in Smokers?
Status: Enrolling
Updated:  1/18/2017
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Zinc Supplements in Lowering Cadmium Levels in Smokers
Do Dietary Supplements of Zinc Reduce Serum Cadmium Levels in Smokers?
Status: Enrolling
Updated: 1/18/2017
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
A Study to See if we Can Predict How Your Liver Tumor or Liver Metastases Will Respond to Trans-Arterial Embolization (TAE)
A PILOT STUDY TO IDENTIFY MOLECULAR PREDICTORS OF SENSITIVITY AND RESISTANCE TO TRANS-ARTERIAL EMBOLIZATION OF PRIMARY LIVER TUMORS AND LIVER METASTASES
Status: Enrolling
Updated:  1/30/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
A Study to See if we Can Predict How Your Liver Tumor or Liver Metastases Will Respond to Trans-Arterial Embolization (TAE)
A PILOT STUDY TO IDENTIFY MOLECULAR PREDICTORS OF SENSITIVITY AND RESISTANCE TO TRANS-ARTERIAL EMBOLIZATION OF PRIMARY LIVER TUMORS AND LIVER METASTASES
Status: Enrolling
Updated: 1/30/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Evolution® Biliary Stent System-Fully Covered
Evaluation for the Effectiveness of Evolution® Biliary Stent System-Fully Covered
Status: Enrolling
Updated:  2/2/2017
University of Colorado Hospital
mi
from
Aurora, CO
Evolution® Biliary Stent System-Fully Covered
Evaluation for the Effectiveness of Evolution® Biliary Stent System-Fully Covered
Status: Enrolling
Updated: 2/2/2017
University of Colorado Hospital
mi
from
Aurora, CO
Click here to add this to my saved trials
Evolution® Biliary Stent System-Fully Covered
Evaluation for the Effectiveness of Evolution® Biliary Stent System-Fully Covered
Status: Enrolling
Updated:  2/2/2017
Borland-Groover Clinic
mi
from
Jacksonville, FL
Evolution® Biliary Stent System-Fully Covered
Evaluation for the Effectiveness of Evolution® Biliary Stent System-Fully Covered
Status: Enrolling
Updated: 2/2/2017
Borland-Groover Clinic
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Evolution® Biliary Stent System-Fully Covered
Evaluation for the Effectiveness of Evolution® Biliary Stent System-Fully Covered
Status: Enrolling
Updated:  2/2/2017
Moffitt Cancer Center
mi
from
Tampa, FL
Evolution® Biliary Stent System-Fully Covered
Evaluation for the Effectiveness of Evolution® Biliary Stent System-Fully Covered
Status: Enrolling
Updated: 2/2/2017
Moffitt Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
Evolution® Biliary Stent System-Fully Covered
Evaluation for the Effectiveness of Evolution® Biliary Stent System-Fully Covered
Status: Enrolling
Updated:  2/2/2017
Indiana University Hospital
mi
from
Indianapolis, IN
Evolution® Biliary Stent System-Fully Covered
Evaluation for the Effectiveness of Evolution® Biliary Stent System-Fully Covered
Status: Enrolling
Updated: 2/2/2017
Indiana University Hospital
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Evolution® Biliary Stent System-Fully Covered
Evaluation for the Effectiveness of Evolution® Biliary Stent System-Fully Covered
Status: Enrolling
Updated:  2/2/2017
Wake Forest Baptist Medical Center
mi
from
Winston-Salem, NC
Evolution® Biliary Stent System-Fully Covered
Evaluation for the Effectiveness of Evolution® Biliary Stent System-Fully Covered
Status: Enrolling
Updated: 2/2/2017
Wake Forest Baptist Medical Center
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Evolution® Biliary Stent System-Fully Covered
Evaluation for the Effectiveness of Evolution® Biliary Stent System-Fully Covered
Status: Enrolling
Updated:  2/2/2017
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Evolution® Biliary Stent System-Fully Covered
Evaluation for the Effectiveness of Evolution® Biliary Stent System-Fully Covered
Status: Enrolling
Updated: 2/2/2017
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Evolution® Biliary Stent System-Fully Covered
Evaluation for the Effectiveness of Evolution® Biliary Stent System-Fully Covered
Status: Enrolling
Updated:  2/2/2017
University of Virginia Health System
mi
from
Charlottesville, VA
Evolution® Biliary Stent System-Fully Covered
Evaluation for the Effectiveness of Evolution® Biliary Stent System-Fully Covered
Status: Enrolling
Updated: 2/2/2017
University of Virginia Health System
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Evolution® Biliary Stent System-Fully Covered
Evaluation for the Effectiveness of Evolution® Biliary Stent System-Fully Covered
Status: Enrolling
Updated:  2/2/2017
St. Michael's Hospital
mi
from
Toronto,
Evolution® Biliary Stent System-Fully Covered
Evaluation for the Effectiveness of Evolution® Biliary Stent System-Fully Covered
Status: Enrolling
Updated: 2/2/2017
St. Michael's Hospital
mi
from
Toronto,
Click here to add this to my saved trials
A Phase II Study of Continuous Hepatic Arterial Infusion With Floxuridine (FUDR) and Dexamethasone (DEX) in Patients With Unresectable Primary Hepatic Malignancy
A Phase II Study of Continuous Hepatic Arterial Infusion With Floxuridine (FUDR) and Dexamethasone (DEX) in Patients With Unresectable Primary Hepatic Malignancy
Status: Enrolling
Updated:  2/6/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
A Phase II Study of Continuous Hepatic Arterial Infusion With Floxuridine (FUDR) and Dexamethasone (DEX) in Patients With Unresectable Primary Hepatic Malignancy
A Phase II Study of Continuous Hepatic Arterial Infusion With Floxuridine (FUDR) and Dexamethasone (DEX) in Patients With Unresectable Primary Hepatic Malignancy
Status: Enrolling
Updated: 2/6/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery
A Randomized, Double-Blinded, Placebo-Controlled Phase II Study of Adjuvant Everolimus Following the Resection of Metastatic Pancreatic Neuroendocrine Tumors to the Liver
Status: Enrolling
Updated:  2/7/2017
Eastern Cooperative Oncology Group
mi
from
Boston, MA
Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery
A Randomized, Double-Blinded, Placebo-Controlled Phase II Study of Adjuvant Everolimus Following the Resection of Metastatic Pancreatic Neuroendocrine Tumors to the Liver
Status: Enrolling
Updated: 2/7/2017
Eastern Cooperative Oncology Group
mi
from
Boston, MA
Click here to add this to my saved trials
Study Comparing Radio Frequency Ablation Plus Chemotherapy and Chemotherapy Alone in Patients With Secondary Liver Metastases
A Prospective, Randomized, Active-Control, Multi-Center Study Assessing Overall Survival Using Chemotherapy With or Without Impedance-Based Radiofrequency Ablation for Subjects With Colorectal Cancer and Incurable Metastatic Liver Disease, Failing at Least First-Line Chemotherapy
Status: Enrolling
Updated:  3/2/2017
New York University
mi
from
New York, NY
Study Comparing Radio Frequency Ablation Plus Chemotherapy and Chemotherapy Alone in Patients With Secondary Liver Metastases
A Prospective, Randomized, Active-Control, Multi-Center Study Assessing Overall Survival Using Chemotherapy With or Without Impedance-Based Radiofrequency Ablation for Subjects With Colorectal Cancer and Incurable Metastatic Liver Disease, Failing at Least First-Line Chemotherapy
Status: Enrolling
Updated: 3/2/2017
New York University
mi
from
New York, NY
Click here to add this to my saved trials
Study Comparing Radio Frequency Ablation Plus Chemotherapy and Chemotherapy Alone in Patients With Secondary Liver Metastases
A Prospective, Randomized, Active-Control, Multi-Center Study Assessing Overall Survival Using Chemotherapy With or Without Impedance-Based Radiofrequency Ablation for Subjects With Colorectal Cancer and Incurable Metastatic Liver Disease, Failing at Least First-Line Chemotherapy
Status: Enrolling
Updated:  3/2/2017
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Study Comparing Radio Frequency Ablation Plus Chemotherapy and Chemotherapy Alone in Patients With Secondary Liver Metastases
A Prospective, Randomized, Active-Control, Multi-Center Study Assessing Overall Survival Using Chemotherapy With or Without Impedance-Based Radiofrequency Ablation for Subjects With Colorectal Cancer and Incurable Metastatic Liver Disease, Failing at Least First-Line Chemotherapy
Status: Enrolling
Updated: 3/2/2017
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated:  3/14/2017
University of Southern California / Keck Hospital
mi
from
Los Angeles, CA
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated: 3/14/2017
University of Southern California / Keck Hospital
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated:  3/14/2017
University of Miami Miller School of Medicine
mi
from
Miami, FL
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated: 3/14/2017
University of Miami Miller School of Medicine
mi
from
Miami, FL
Click here to add this to my saved trials
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated:  3/14/2017
Florida Hospital Transplant Institute
mi
from
Orlando, FL
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated: 3/14/2017
Florida Hospital Transplant Institute
mi
from
Orlando, FL
Click here to add this to my saved trials
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated:  3/14/2017
Piedmont Hospital
mi
from
Atlanta, GA
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated: 3/14/2017
Piedmont Hospital
mi
from
Atlanta, GA
Click here to add this to my saved trials
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated:  3/14/2017
Emory University School of Medicine
mi
from
Atlanta, GA
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated: 3/14/2017
Emory University School of Medicine
mi
from
Atlanta, GA
Click here to add this to my saved trials
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated:  3/14/2017
Northwestern Memorial Hospital
mi
from
Chicago, IL
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated: 3/14/2017
Northwestern Memorial Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated:  3/14/2017
University of Kentucky Chandler Medical Center
mi
from
Lexington, KY
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated: 3/14/2017
University of Kentucky Chandler Medical Center
mi
from
Lexington, KY
Click here to add this to my saved trials
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated:  3/14/2017
Ochsner Medical Center
mi
from
New Orleans, LA
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated: 3/14/2017
Ochsner Medical Center
mi
from
New Orleans, LA
Click here to add this to my saved trials
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated:  3/14/2017
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated: 3/14/2017
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated:  3/14/2017
Lahey Hospital
mi
from
Burlington, MA
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated: 3/14/2017
Lahey Hospital
mi
from
Burlington, MA
Click here to add this to my saved trials
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated:  3/14/2017
Mount Sinai Hospital
mi
from
New York, NY
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated: 3/14/2017
Mount Sinai Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated:  3/14/2017
Columbia University College of Physicians and Surgeons
mi
from
New York, NY
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated: 3/14/2017
Columbia University College of Physicians and Surgeons
mi
from
New York, NY
Click here to add this to my saved trials
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated:  3/14/2017
Oregon Health and Science University
mi
from
Portland, OR
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated: 3/14/2017
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated:  3/14/2017
Methodist University Hospital
mi
from
Memphis, TN
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated: 3/14/2017
Methodist University Hospital
mi
from
Memphis, TN
Click here to add this to my saved trials
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated:  3/14/2017
Vanderbilt University Medical Center
mi
from
Nashville, TN
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated: 3/14/2017
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated:  3/14/2017
Baylor University Medical Center
mi
from
Dallas, TX
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated: 3/14/2017
Baylor University Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials